GlassScriptPhysician profile
Andrea B Lantz
NPI 1164412318
$8,841.58
in general payments reported to CMS, 2019-2025
32 companies · $1,256 in 2025
The $1,256 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,061 · 2020: $807 · 2021: $1,423 · 2022: $1,522 · 2023: $1,268 · 2024: $1,504 · 2025: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,028.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,190.40 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Genzyme Corporation | $1,170.72 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,140.99 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $895.89 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Pfizer INC. | $710.27 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $526.31 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $388.58 | 2019-2025 | Nucala, Trelegy Ellipta |
| Abbvie INC. | $338.41 | 2022-2025 | |
| Biocryst US Sales Co., LLC | $322.96 | 2021-2025 | Orladeyo |
| Grifols USA, LLC | $251.06 | 2019-2025 | Xembify |
| Amgen INC. | $244.12 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $207.76 | 2019-2025 | Xolair |
| Kaleo, INC. | $206.75 | 2019-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $169.47 | 2019-2025 | |
| Octapharma USA, INC. | $159.34 | 2019-2023 | Cutaquig |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $150.11 | 2019-2022 | |
| Pharming Healthcare, INC. | $145.18 | 2021-2025 | Ruconest |
| Covis Pharma Gmbh | $81.59 | 2021-2022 | |
| Bio Products Laboratory USA, INC. | $77.56 | 2021-2022 | |
| Leo Pharma INC. | $65.78 | 2022-2024 | Adbry |
| Hospira, INC. | $52.74 | 2020-2021 | |
| Incyte Corporation | $45.36 | 2021-2022 | |
| Ionis Pharmaceuticals, INC. | $44.16 | 2025 | Dawnzera |
| Shire North American Group INC | $43.95 | 2019 | |
| Cycle Pharmaceuticals INC | $41.01 | 2025 | Sajazir |
| Alk-Abello, INC | $37.09 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $32.82 | 2025 | Xhance |
| Lilly USA, LLC | $25.78 | 2024 | Ebglyss |
| Teva Pharmaceuticals USA, INC. | $23.61 | 2020 | |
| Gilead Sciences, INC. | $18.98 | 2023 | |
| Biocryst Pharmaceuticals, INC. | $16.71 | 2020 | |
| Hikma Pharmaceuticals USA | $16.12 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Lantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.